MétaCan
Menu
Back to cohort
Record W2163692526 · doi:10.1310/vqxj-41x6-gja2-h6ag

Effect of Protease Inhibitor-Based Highly Active Antiretroviral Therapy on Survival in HIV-Associated Advanced Kaposi's Sarcoma Patients Treated with Chemotherapy

2003· article· en· W2163692526 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueHIV Clinical Trials · 2003
Typearticle
Languageen
FieldMedicine
TopicViral-associated cancers and disorders
Canadian institutionsMcGill University Health CentreUniversity of British ColumbiaBC Cancer Agency
Fundersnot available
KeywordsMedicineChemotherapyInternal medicineVincristineRegimenSarcomaGastroenterologyIndinavirChemotherapy regimenAnthracyclineProtease inhibitor (pharmacology)SurgeryViral loadHuman immunodeficiency virus (HIV)Antiretroviral therapyImmunologyCyclophosphamidePathologyCancer

Abstract

fetched live from OpenAlex

OBJECTIVE: To determine whether the use of protease inhibitor (PI)-based antiretroviral (ARV) therapy had an impact on the survival of patients with human immunodeficiency virus (HIV) infection-associated Kaposi's sarcoma (KS) who were receiving systemic chemotherapy. METHOD: Records of 48 AIDS patients with extensive KS who received chemotherapy from 1995 to 1999 were reviewed. Analysis by presence or absence of PI treatment was undertaken, and patients who were receiving nonnucleoside reverse transcriptase inhibitors (NNRTIs) were excluded from the analysis. RESULTS: Median age was 38 years, and 47 patients were men having sex with men. Half of the patients (54%) had at least one prior AIDS-defining event. Median CD4 count at diagnosis of KS was 28 cells/microL (range, 1-625). Visceral KS was present in 33 patients (69%), and the remainder of patients had extensive and symptomatic cutaneous and/or mucous membrane involvement. All patients received at least one cycle of chemotherapy, including vincristine/bleomycin or an anthracycline-containing regimen. There was a significant difference in the median survival (MS) between the 28 patients (58%) treated with PI-based antiretroviral therapy (31 months [range, 1.8-48]) and the group not receiving PI (7 months [range, 1-28], p =.0001). In addition, 81% of patients in the PI group were alive at 18 months from initiation of chemotherapy versus 12% in the non-PI group. Twenty patients (71%) in the PI-treated group were able to discontinue chemotherapy for at least 1 month after remission of KS, in comparison to 3 of 20 (15%) patients in the group of patients who did not receive PI (p =.00001). Death due to KS occurred in 6 of 28 (21%) patients (total 9 deaths) in the PI group and 14 of 20 (70%) patients (total 18 deaths) in the non-PI group (p =.001). CONCLUSION: In a nonselected group of patients with advanced and extensive KS in a real-life clinical setting, our results show a survival benefit and a decrease in KS-related death for patients receiving chemotherapy and PI-based ARV therapy when compared to patients not receiving PI-based therapy. Discontinuation of chemotherapy in patients receiving PI-based antiretroviral therapy appears to be feasible in patients who attain remission of KS.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Direct model labels (unvalidated)

Per-model category and study-design labels from the labeling rounds. They are machine output, unvalidated, and the disagreement between models ships as data. No study design here is MEDLINE-validated yet.

Model armCategoriesStudy designConfidence
gemmano category
Domain: not available · Genre: Empirical
About the Canadian research system: no · About a Canadian topic: no
Non-randomized triallow
gptno category
Domain: not available · Genre: Empirical
About the Canadian research system: no · About a Canadian topic: no
Other designhigh
models splitAgreement compares identical category sets and study designs across arms.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.009
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.445
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0050.009
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.045
GPT teacher head0.377
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it